By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Resverlogix Corporation 

4820 Richard Road SW
Suite 300
Calgary  Alberta  T3E 6L1  Canada
Phone: 403-254-9252 Fax: 403-256-8495


Company News
Resverlogix (RVX.TO) Files 2016 Year-End Disclosure Documents 7/28/2016 10:23:38 AM
Resverlogix (RVX.TO) Announces Dosing Of First Two Patients In Expanded Renal And Orphan Programs 7/22/2016 6:39:29 AM
Resverlogix (RVX.TO) Announces Corporate Update Webcast 6/9/2016 3:23:31 PM
BIO2016: Resverlogix (RVX.TO) Announces Lead Drug Apabetalone Publication And Presentation At BIO International 2016 6/2/2016 8:45:59 AM
Resverlogix (RVX.TO) Presents New Complement Data And Establishes Renal Clinical Advisory Board At The 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 5/25/2016 7:40:17 AM
The New York Academy of Sciences Collaborates With Resverlogix (RVX.TO) To Host Epigenetics Symposium 4/18/2016 8:33:22 AM
Resverlogix (RVX.TO) Further Strengthens The Board Of Directors And Appoints A New Chairman 4/4/2016 7:48:07 AM
Resverlogix (RVX.TO) Announces Corporate Update Webcast 3/2/2016 10:33:50 AM
Resverlogix (RVX.TO)'s Manuscript On BET-Inhibitor apabetalone (RVX-208) Accepted Into The Atherosclerosis Journal 1/26/2016 11:09:08 AM
Resverlogix (RVX.TO) Commences Dosing In Phase 3 Clinical Trial Betonmace 11/11/2015 8:52:09 AM